Zobrazeno 1 - 10
of 188
pro vyhledávání: '"David, Belada"'
Autor:
Alice Sýkorová, František Folber, Kamila Polgárová, Heidi Móciková, Juraj Ďuraš, Kateřina Steinerová, Aleš Obr, Adriana Heindorfer, Miriam Ladická, Ľubica Lukáčová, Erika Čellárová, Ivana Plameňová, David Belada, Andrea Janíková, Marek Trněný, Tereza Jančárková, Vít Procházka, Andrej Vranovský, Margaréta Králiková, Jan Vydra, Lukáš Smolej, Ľuboš Drgoňa, Martin Sedmina, Eva Čermáková, Robert Pytlík
Publikováno v:
Cancer Medicine, Vol 13, Iss 17, Pp n/a-n/a (2024)
Abstract Aim The aim of this study was to analyse the outcomes of patients with large B‐cell lymphoma (LBCL) treated with chimeric antigen receptor T‐cell therapy (CAR‐Tx), with a focus on outcomes after CAR T‐cell failure, and to define the
Externí odkaz:
https://doaj.org/article/613627563fa145bcad4718e937c66eed
Autor:
Pavel Vodárek, Dominika Écsiová, Vladimíra Řezáčová, Ondřej Souček, Martin Šimkovič, Doris Vokurková, David Belada, Pavel Žák, Lukáš Smolej
Publikováno v:
Cancer Medicine, Vol 13, Iss 15, Pp n/a-n/a (2024)
Abstract Introduction The impact of chemoimmunotherapy (CIT) on immunoglobulin (Ig) quantities in patients with chronic lymphocytic leukemia (CLL) has not been extensively studied. Methods We analyzed Ig levels in 45 stable patients with indolent CLL
Externí odkaz:
https://doaj.org/article/ab5ccf42e2684a0aabf0f605607b37be
Autor:
Pavel Vodárek, Dominika Écsiová, Vladimíra Řezáčová, Ondřej Souček, Martin Šimkovič, Doris Vokurková, David Belada, Pavel Žák, Lukáš Smolej
Publikováno v:
Cancer Medicine, Vol 12, Iss 6, Pp 6956-6970 (2023)
Abstract Background In chronic lymphocytic leukemia (CLL), changes in the peripheral blood lymphocyte subsets play an important role in disease progression and infectious complications. The impact of chemoimmunotherapy (CIT) on these changes has not
Externí odkaz:
https://doaj.org/article/2422169dc87b49f79bc7174866fc2304
Autor:
Marek Trněný, Abraham Avigdor, Matthew S. McKinney, Shankara Paneesha, Björn E. Wahlin, John S. Hrom, David Cunningham, Nicholas Morley, Miguel Canales, Mariana Bastos-Oreiro, David Belada, Liliana Devizzi, Fred Zheng, Douglas J. DeMarini, Wei Jiang, Ping Jiang, Ryan C. Lynch
Publikováno v:
EClinicalMedicine, Vol 63, Iss , Pp 102130- (2023)
Summary: Background: Parsaclisib, a potent and highly selective PI3Kδ inhibitor, has shown clinical benefit in patients with relapsed or refractory (R/R) B-cell malignancies. This phase 2 study (CITADEL-203; NCT03126019, EudraCT 2017-001624-22) asse
Externí odkaz:
https://doaj.org/article/c66821b07c654aec8c095879560486da
Autor:
Anna Sureda, Lorenzo Falchi, Sirpa Leppa, Joost Vermaat, Harald Holte, Martin Hutchings, Pieternella Lugtenburg, Sven de Vos, Pau Abrisqueta, Marcel Nijland, Reid W. Merryman, Jacob Haaber Christensen, Bjorn Wahlin, Kim Linton, Liwei Wang, Aqeel Abbas, Ali Rana, Syed Quadri, David Belada
Publikováno v:
HemaSphere, Vol 7, p e5547136 (2023)
Externí odkaz:
https://doaj.org/article/327f7aeaa4ac4754846a26ed47c7ba62
Autor:
Michael Roost Clausen, David Belada, Fritz Offner, Sven de Vos, Joshua Brody, Kim Linton, Sylvia Snauwaert, Raul Cordoba, Jun Wu, Irina Bykhovski, Liwei Wang, Ali Rana, Lorenzo Falchi
Publikováno v:
HemaSphere, Vol 7, p e55140cd (2023)
Externí odkaz:
https://doaj.org/article/60cb36dc2c9040eeab31847d55e92ef0
Autor:
Heidi Mocikova, Jana Markova, Lubica Gaherova, Maria Maco, Alice Sýkorová, David Belada, Marie Lukášová, Vit Prochazka, Juraj Duras, Tomas Kozak
Publikováno v:
HemaSphere, Vol 6, Pp 11-12 (2022)
Externí odkaz:
https://doaj.org/article/535d17014f5a43eb85eafc11ad9b2654
Autor:
Heidi Mocikova, Robert Pytlík, Katerina Benesova, Andrea Janikova, Juraj Duras, Alice Sykorova, Katerina Steinerova, Vit Prochazka, Vit Campr, David Belada, Marek Trneny
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionWe analyzed the incidence, risk factors of central nervous system (CNS) relapse, and outcome of CNS involvement in patients with peripheral T-cell lymphomas (PTCL) from the Czech Lymphoma Study Group Registry NiHiL (Clinical Trial gov. NC
Externí odkaz:
https://doaj.org/article/de7be5e1b9b64877ad8935cf67565a06
Autor:
Vít Procházka, David Belada, Andrea Janíková, Kateřina Benešová, Heidi Mociková, Juraj Ďuraš, Jan Pirnos, Kateřina Kopečková, Vít Campr, Tomáš Fürst, Robert Pytlík, Alice Sýkorová, Jozef Michalka, Jitka Dlouhá, Tomáš Papajík, Marek Trněný
Publikováno v:
eJHaem, Vol 1, Iss 1, Pp 170-180 (2020)
Abstract Twenty percent of patients with high‐tumor‐burden (HTB) follicular lymphoma (FL) develop progression/relapse of disease (POD) within 24 months of frontline immunochemotherapy. Unfortunately, about 50% of these patients die within 5 years
Externí odkaz:
https://doaj.org/article/36f7a329607444baa20175f7789312f1
Autor:
Vit Prochazka, Heidi Mocikova, Alice Sykorova, Jana Markova, Marie Lukášová, Lubica Gaherova, Alexandra Kredatusova, Eva Kriegova, Maria Maco, Tomas Kozak, David Belada, Tomas Papajik
Publikováno v:
HemaSphere, Vol 6, Pp 21-21 (2022)
Externí odkaz:
https://doaj.org/article/1d9c54a116704f7d8c18c3786ca6f9f9